The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.
Saved in:
| Title: | The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. |
|---|---|
| Authors: | Hicks SW; ImmunoGen, Inc., Waltham, MA. Electronic address: stuart.hicks@immunogen.com., Lai KC; ImmunoGen, Inc., Waltham, MA., Gavrilescu LC; ImmunoGen, Inc., Waltham, MA., Yi Y; ImmunoGen, Inc., Waltham, MA., Sikka S; ImmunoGen, Inc., Waltham, MA., Shah P; ImmunoGen, Inc., Waltham, MA., Kelly ME; ImmunoGen, Inc., Waltham, MA., Lee J; ImmunoGen, Inc., Waltham, MA., Lanieri L; ImmunoGen, Inc., Waltham, MA., Ponte JF; ImmunoGen, Inc., Waltham, MA., Sloss CM; ImmunoGen, Inc., Waltham, MA., Romanelli A; ImmunoGen, Inc., Waltham, MA. |
| Source: | Neoplasia (New York, N.Y.) [Neoplasia] 2017 Sep; Vol. 19 (9), pp. 661-671. Date of Electronic Publication: 2017 Jul 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1476-5586 |
|---|---|
| DOI: | 10.1016/j.neo.2017.06.001 |